ReviewDiscover oncology2025
Targeting estrogen receptor alpha in breast cancer for novel therapies resistance mechanisms and future directions.
Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Selective Induction of Estrogen Receptor-Dependent Stress Signaling as a Therapeutic Strategy in Resistant Breast Cancer.ACS medicinal chemistry letters · 2026Article
- Nanovesicle-formulatedJournal of advanced pharmaceutical technology & researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Estrogen receptor α (ERα) is a key therapeutic target in ER-positive breast cancer. Structurally, ERα contains activation function (AF) domains that drives breast cancer proliferation, metastasis, and drug resistance through classical genomic, non-genomic, and ligand-independent signaling pathways. Clinically approved and investigational drugs targeting Erα include selective estrogen receptor modulators (SERMs), selective estrogen receptor downregulators/degraders (SERDs), and novel strategies such as proteolysis-targeting chimeras (PROTACs). Current research focuses on overcoming endocrine resistance via combination therapies targeting mutations in ESR1, the gene encoding ERα, non-genomic signaling pathways, and the tumor microenvironment, which may advance precision medicine in breast cancer. This article summarizes recent advances in ERα-targeting inhibitors and their therapeutic implications, to provide potential precision therapeutic strategies for breast cancer patients with ER positive.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.